Cite
Dührsen U, Tometten M, Kroschinsky F, et al. Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. Blood Cancer J. 2021;11(5):95doi: 10.1038/s41408-021-00485-5.
Dührsen, U., Tometten, M., Kroschinsky, F., Ganser, A., Ibach, S., Bertram, S., & Hüttmann, A. (2021). Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. Blood cancer journal, 11(5), 95. https://doi.org/10.1038/s41408-021-00485-5
Dührsen, Ulrich, et al. "Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma." Blood cancer journal vol. 11,5 (2021): 95. doi: https://doi.org/10.1038/s41408-021-00485-5
Dührsen U, Tometten M, Kroschinsky F, Ganser A, Ibach S, Bertram S, Hüttmann A. Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphoma. Blood Cancer J. 2021 May 17;11(5):95. doi: 10.1038/s41408-021-00485-5. PMID: 34001867; PMCID: PMC8129096.
Copy
Download .nbib